BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,080 filers reported holding BAXTER INTL INC in Q3 2020. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Haverford Financial Services, Inc. | 94,721 | $7,617,000 | 2.34% |
| Avidity Partners Management LP | 620,000 | $49,860,000 | 2.31% |
| Canal Insurance CO | 70,000 | $5,629,000 | 2.26% |
| BROWN BROTHERS HARRIMAN & CO | 3,676,061 | $295,629,000 | 2.12% |
| RTW INVESTMENTS, LP | 1,077,268 | $86,634,000 | 2.09% |
| ORSER CAPITAL MANAGEMENT, LLC | 30,165 | $2,426,000 | 1.92% |
| Barbara Oil Co. | 40,000 | $3,217,000 | 1.76% |
| Mawer Investment Management Ltd. | 3,246,111 | $261,052,000 | 1.71% |
| Argyle Capital Management Inc. | 51,520 | $4,143,000 | 1.70% |
| CCM INVESTMENT ADVISERS LLC | 129,693 | $10,429,000 | 1.69% |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 7,874,269 | $633,249,000 | 1.69% |
| Bedell Frazier Investment Counselling, LLC | 56,505 | $4,544,000 | 1.62% |
| Running Oak Capital LLC | 55,133 | $4,434,000 | 1.62% |
| Providence Capital Advisors, LLC | 37,500 | $3,016,000 | 1.59% |
| Haverford Trust Co | 1,235,459 | $99,356,000 | 1.58% |
| SEARLE & CO. | 36,084 | $2,902,000 | 1.58% |
| Carmignac Gestion | 1,649,620 | $132,660,000 | 1.57% |
| Teza Capital Management LLC | 32,471 | $2,611,000 | 1.53% |
| Cumberland Partners Ltd | 181,435 | $14,591,000 | 1.53% |
| DELTA ASSET MANAGEMENT LLC/TN | 157,511 | $12,667,000 | 1.52% |
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BAXTER INTL INC's shareholders in Q3 2020. To view BAXTER INTL INC's shareholder history, click here.